Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-1.23%
SPX
-1.60%
IXIC
-2.24%
FTSE
-0.70%
N225
-0.66%
AXJO
-0.92%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
988.30M
Dividend Yield
0.00%
P/E Ratio
-5.46
EPS
-2.35
Revenue
32.33M
Avg. Volume
-

About

What does VERV do?
Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
Sector
💻 Health Care
IPO
CEO
Employees
255 employees
Headquarters
Massachusetts, USA
Stocks
Health Care
verv
Verve Therapeutics
NASDAQ: VERV
0.00 (0.00%)
11.13
USD
At close at Aug 01, 20:45 UTC
Summary
News
Signals
Benchmarks
Financials

Recently from Cashu

publisher logo
Cashu

Verve Therapeutics: Embracing Innovative Mosquito Control for Public Health Solutions

8 months ago